COYA 303
Alternative Names: COY303; COYA 301 + GLP-1 receptor agonist - Coya Therapeutics; COYA-303Latest Information Update: 12 Nov 2025
At a glance
- Originator Coya Therapeutics
- Class Anti-inflammatories; Interleukins
- Mechanism of Action Glucagon-like peptide-1 receptor agonists; Interleukin 2 replacements; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 05 Nov 2025 Pharmacodynamics data from a preclinical studies in Inflammation released by Coya Therapeutics
- 16 Sep 2025 Pharmacodynamics data from preclinical study in Inflammation released by Coya Therapeutics
- 21 Apr 2025 Pharmacodynamics data from preclinical study in Inflammation released by Coya Therapeutics